Type 2 Diabetes

The hemoglobin A1C test underestimates the prevalence of diabetes in patients, shows new research presented at ENDO 2019.

An assessment of the world's largest twin registry found telling patterns of common autoimmune diseases including type 1 diabetes.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

A new Puerto Rico-based trial shows that patients on add-on SGLT-2 inhibitors reported greater HbA1C reductions.

The FDA’s decision regarding sotagliflozin (Zynquista), an investigational treatment for type 1 diabetes, followed a split Advisory Committee vote in January.

The applications seek FDA approval for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes.

Diabetic retinopathy is the leading cause of blindness among working adults in the United States, but disease pathways may vary between patients, new research shows.

Fulminant type 1 diabetes is rare, sudden and often deadly. New research published in the journal Diabetes describes a key discovery that could lead to new treatments for this condition.

Among participants of the EMPA-REG OUTCOME trial who experienced heart failure, empagliflozin was associated with lower rates of short-term re-hospitalization and death.

A new study of a blood pressure-monitoring mobile app reports patients with diabetes could reach better thresholds.

A 3 million-plus patient longitudinal study found the drug class was no worse for amputation risks than other diabetes therapies, despite recent conflicting studies.

Now that SGLT-2 inhibitors have reached the market, how will clinicians compare their benefits in patients?

How the effective cardiovascular drug class have reach a state of impending head-to-head trials.

A prospective study found that daily dapagliflozin significantly improved mitral flow, left ventricular mass index, and left atrial volume index after 6 months of treatment.

No head-to-head trials exist for the inhibitors, but current data shows consistency across the board for each drug.